Cystatin D is a candidate tumor suppressor gene induced by vitamin D in human colon cancer cells
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The active vitamin D metabolite 1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3] has wide but not fully understood antitumor activity. A previous transcriptomic analysis of 1alpha,25(OH)2D3 action on human colon cancer cells revealed cystatin D (CST5), which encodes an inhibitor of several cysteine proteases of the cathepsin family, as a candidate target gene. Here we report that 1alpha,25(OH)2D3 induced vitamin D receptor (VDR) binding to, and activation of, the CST5 promoter and increased CST5 RNA and protein levels in human colon cancer cells. In cells lacking endogenous cystatin D, ectopic cystatin D expression inhibited both proliferation in vitro and xenograft tumor growth in vivo. Furthermore, cystatin D inhibited migration and anchorage-independent growth, antagonized the Wnt/beta-catenin signaling pathway, and repressed c-MYC expression. Cystatin D repressed expression of the epithelial-mesenchymal transition inducers SNAI1, SNAI2, ZEB1, and ZEB2 and, conversely, induced E-cadherin and other adhesion proteins. CST5 knockdown using shRNA abrogated the antiproliferative effect of 1alpha,25(OH)2D3, attenuated E-cadherin expression, and increased c-MYC expression. In human colorectal tumors, expression of cystatin D correlated with expression of VDR and E-cadherin, and loss of cystatin D correlated with poor tumor differentiation. Based on these data, we propose that CST5 has tumor suppressor activity that may contribute to the antitumoral action of 1alpha,25(OH)2D3 in colon cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121
Colorectal cancer and genetic alterations in the Wnt pathway
Segditsas, S., & Tomlinson, I. (2006) · Oncogene · doi:10.1038/sj.onc.1210059 · Cited by 591
Cystatin C Antagonizes Transforming Growth Factor β Signaling in Normal and Cancer Cells
Sokol, J. P., & Schiemann, W. P. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.183.2.3 · Cited by 121
Cited by
Hon, G. C., Hawkins, R. D., Caballero, O. L., Lo, C., Lister, R., Pelizzola, M., Valsesia, A., Ye, Z., Kuan, S., Edsall, L. E., et al. (2012) · Genome Research · doi:10.1101/gr.125872.111 · Cited by 583
An update on vitamin D signaling and cancer
Carlberg, C., & Muñoz, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.018 · Cited by 281
Self-citationPereira, F., Barbáchano, A., Silva, J., Bonilla, F., Campbell, M. J., Muñoz, A., & Larriba, M. J. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr399 · Cited by 177
“In line with this, the induction of CDH1/Ecadherin RNA and also that of CYP24A1 and CST5/cystatin D, two other 1,25(OH)2D3 targets (35,36), was inhibited in shJMJD3 cells (Fig.”
BackgroundSelf-citationPlausible ergogenic effects of vitamin D on athletic performance and recovery
Dahlquist, D. T., Dieter, B. P., & Koehle, M. S. (2015) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-015-0093-8 · Cited by 151
PPP2R5A: A multirole protein phosphatase subunit in regulating cancer development
Mao, Z., Liu, C., Lin, X., Sun, B., & Su, C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.024 · Cited by 30
Metadata
- Authors
- ρlvarez-Díaz, S., Valle, N., García, J. M., Peña, C., Freije, J. M. P., Quesada, V., Astudillo, A., Bonilla, F., López-Otín, C., & Muñoz, A.
- Venue
- Journal of Clinical Investigation
- Published
- 2009-08-03
- Volume
- 119
- Issue
- 8
- Pages
- 2343-2358
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2001749073
- Cited by
- 132
- References
- 3
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.